Kári Stefánsson

Fauna Bio Analyzes Largest Set Of Mammalian Genomes To Advance Biomedical Research

Retrieved on: 
Wednesday, November 11, 2020
Branches of biology, Genomics, Biology, Genetic mapping, Genome, Microbiology, Molecular biology, Pathogenomics, Kári Stefánsson

The dataset includes genomes from more than 120 species that were not previously sequenced and captures mammalian diversity at an unprecedented scale.

Key Points: 
  • The dataset includes genomes from more than 120 species that were not previously sequenced and captures mammalian diversity at an unprecedented scale.
  • Researchers can use the data to compare the genomes of humans and other mammals, which could help identify genomic regions that might be involved in human disease.
  • Fauna Bio is focused on using the data not only to better understand which mutations contribute to human disease but also to pinpoint genes involved in animal disease resistance.
  • The Zoonomia Project builds on a previous project, the 29 Mammals Project , which began sequencing mammalian genomes in 2006.

SomaLogic Announces New Agreement with Amgen to Accelerate Drug Discovery and Development Efforts Through Comprehensive Proteomic Profiling

Retrieved on: 
Thursday, July 30, 2020
Health, Biotechnology companies, Amgen, deCODE genetics, Clinical trial, Proteomics, Kári Stefánsson

BOULDER, Colo., July 30, 2020 (GLOBE NEWSWIRE) -- SomaLogic, Inc. announced today an agreement with Amgen that will use SomaLogics proprietary proteomics technology to help advance Amgens drug discovery and development programs.

Key Points: 
  • BOULDER, Colo., July 30, 2020 (GLOBE NEWSWIRE) -- SomaLogic, Inc. announced today an agreement with Amgen that will use SomaLogics proprietary proteomics technology to help advance Amgens drug discovery and development programs.
  • The agreement builds upon SomaLogics existing collaboration with deCODE genetics , an Amgen subsidiary based in Iceland, and will include broader application across Amgens pipeline.
  • This new agreement will further enhance these efforts as we seek to enable the discovery of new drug targets and identify the individuals who will respond to specific treatments being developed by Amgen.
  • Under the terms of the new agreement, SomaLogic will analyze more than 40,000 samples, including samples from Amgen clinical trials.

deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants

Retrieved on: 
Wednesday, September 11, 2019
Branches of biology, Biological databases, Genetics, Biology, Wellcome Trust, UK Biobank, deCODE genetics, Biobank, Whole genome sequencing, Wellcome Sanger Institute, Cathie Sudlow, Kári Stefánsson

REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ --deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants.

Key Points: 
  • REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ --deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants.
  • The project will allow the complete sequencing of the genetic code of all 500,000 participants in the UK Biobank.
  • The UK Biobank is an extraordinary resource for medical research that Great Britain has built over the past 15 years.
  • The Whole Genome Sequencing of the UK Biobank participants will be performed by deCODE genetics together with the Wellcome Sanger Institute in the UK with an anticipated completion in the summer of 2021.

deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants

Retrieved on: 
Wednesday, September 11, 2019
Branches of biology, Biological databases, Genetics, Biology, Wellcome Trust, UK Biobank, deCODE genetics, Biobank, Whole genome sequencing, Wellcome Sanger Institute, Cathie Sudlow, Kári Stefánsson

REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ --deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants.

Key Points: 
  • REYKJAVIK, Iceland, Sept. 11, 2019 /PRNewswire/ --deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants.
  • The project will allow the complete sequencing of the genetic code of all 500,000 participants in the UK Biobank.
  • The UK Biobank is an extraordinary resource for medical research that Great Britain has built over the past 15 years.
  • The Whole Genome Sequencing of the UK Biobank participants will be performed by deCODE genetics together with the Wellcome Sanger Institute in the UK with an anticipated completion in the summer of 2021.